Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL

被引：115
|
作者：
Maude, Shannon L.
Teachey, David T.
Rheingold, Susan R.
Shaw, Pamela A.
Aplenc, Richard
Barrett, David Maxwell
Barker, Christine S.
Callahan, Colleen
Frey, Noelle V.
Nazimuddin, Farzana
Lacey, Simon F.
Zheng, Zhaohui
Levine, Bruce
Melenhorst, Jan Joseph
Motley, Laura
Porter, David L.
June, Carl H.
Grupp, Stephan A.
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA USA
[2] Univ Pennsylvania, Philadelphia, PA USA
[3] Univ Pennsylvania, Abramson Canc Ctr, Philadelphia, PA USA
[4] Univ Pennsylvania, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA USA
[5] Univ Pennsylvania, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Maude, Shannon L.
    Hucks, George E.
    Callahan, Colleen
    Baniewicz, Diane
    Fasano, Christina
    Barker, Christine
    Rheingold, Susan R.
    Aplenc, Richard
    Dinofia, Amanda M.
    Li, Amanda
    Teachey, David T.
    Barrett, David M.
    Brogdon, Jennifer
    Young, Regina M.
    Scholler, John
    Marcucci, Katherine T.
    Levine, Bruce L.
    Frey, Noelle
    Porter, David L.
    Lacey, Simon F.
    Melenhorst, J. Joseph
    June, Carl H.
    Grupp, Stephan A.
    BLOOD, 2017, 130
  • [22] T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL
    Grupp, Stephan A.
    Maude, Shannon L.
    Shaw, Pamela
    Aplenc, Richard
    Barrett, David M.
    Callahan, Colleen
    Chew, Anne
    Lacey, Simon F.
    Levine, Bruce L.
    Melenhorst, J. Joseph
    Motley, Laura
    Rheingold, Susan R.
    Shen, Angela
    Teachey, David T.
    Wood, Patricia A.
    Porter, David L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [23] Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
    Turtle, Cameron J.
    Hay, Kevin A.
    Hanafi, Laila-Aicha
    Li, Daniel
    Cherian, Sindhu
    Chen, Xueyan
    Wood, Brent
    Lozanski, Arletta
    Byrd, John C.
    Heimfeld, Shelly
    Riddell, Stanley R.
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3010 - +
  • [24] Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia
    Cao, Jiang
    Cheng, Hai
    Qi, Kunming
    Chen, Wei
    Shi, Ming
    Zheng, Junnian
    Xu, Kailin
    BLOOD, 2019, 134
  • [25] Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    Maude, Shannon L.
    Frey, Noelle
    Shaw, Pamela A.
    Aplenc, Richard
    Barrett, David M.
    Bunin, Nancy J.
    Chew, Anne
    Gonzalez, Vanessa E.
    Zheng, Zhaohui
    Lacey, Simon F.
    Mahnke, Yolanda D.
    Melenhorst, Jan J.
    Rheingold, Susan R.
    Shen, Angela
    Teachey, David T.
    Levine, Bruce L.
    June, Carl H.
    Porter, David L.
    Grupp, Stephan A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16): : 1507 - 1517
  • [26] Clinically Adaptable CD19-Specific Chimeric Antigen Receptor
    Diaconu, Iulia
    Savoldo, Barbara
    Dotti, Gianpietro
    MOLECULAR THERAPY, 2014, 22 : S64 - S64
  • [27] Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Maude, Shannon L.
    Barrett, David M.
    Rheingold, Susan R.
    Aplenc, Richard
    Teachey, David T.
    Callahan, Colleen
    Baniewicz, Diane
    White, Claire
    Talekar, Mala K.
    Shaw, Pamela A.
    Brogdon, Jennifer L.
    Young, Regina M.
    Scholler, John
    Marcucci, Katherine T.
    Levine, Bruce L.
    Frey, Noelle
    Porter, David L.
    Lacey, Simon F.
    Melenhorst, J. Joseph
    June, Carl H.
    Grupp, Stephan A.
    BLOOD, 2016, 128 (22)
  • [28] Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL
    Curran, Kevin J.
    Riviere, Isabelle
    Kobos, Rachel
    Kernan, Nancy A.
    Boulad, Farid
    Prockop, Susan E.
    Scaradavou, Andromachi
    Renaud, Thomas M.
    Shukla, Neerav
    Steinherz, Peter G.
    Park, Jae H.
    Sauter, Craig S.
    O'Reilly, Richard J.
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2014, 124 (21)
  • [29] Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor-(CAR-) modified T cells.
    Turtle, Cameron John
    Hay, Kevin Anthony
    Gust, Juliane
    Hanafi, Laila-Aicha
    Li, Daniel
    Liles, W. Conrad
    Wurfel, Mark
    Harju-Baker, Susanna
    Myerson, David
    Gonzalez-Cuyar, Luis
    Yeung, Cecilia C. S.
    Riddell, Stanley R.
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).
    Newman, Haley
    Leahy, Allison Emily Barz
    Li, Yimei
    Liu, Hongyan
    Myers, Regina M.
    DiNofia, Amanda M.
    Dolan, Joseph Gregory
    Callahan, Colleen
    Devine, Kaitlin J.
    Wray, Lisa
    June, Carl H.
    Grupp, Stephan A.
    Rheingold, Susan R.
    Maude, Shannon L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345